Board summary
Key figures
48,358
Registered population
62.1% aged 18–64
14.5%
Aged 65+
ICB 14.9% · England 17.9%
19.8%
Ethnic minority (non-White)
13.8% Asian · England 9.6%
46.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~17,800
Core20 residents (est.)
Resident basis; registered basis ~23,388 · see page 3
6,910
Hypertension register
+8.04% in 3 yrs · England +5.60%
579
SMI register
23.2% of Bury (LAD)'s
1,058
COPD register
Reviews +14.36% in 3 yrs
Forecast to 2030
8,162
Hypertension patients, 2030
+1,252 on today
84.2%
QRISK ≥20% on statins, 2030
+5.80pp over 3 yrs
3.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell behind local and national.
Asthma reviews fell -1.8% over 2023 to 2025 to 62.5% (England 65.7%, Bury (LAD) 64.2%), leaving a scale estimate of 1,190 patients unreviewed.
Annual physical health checks lag for SMI patients.
SMI blood pressure checks reached 76.2% (England 83.4%) and BMI checks 75.3% (England 82.1%), which may reflect recall gaps to test by audit.
Population, age and ethnicity
A 23.4% child share and 13.8% Asian population may shape primary care demand
Bury PCN serves 48,358 registered patients across eight practices. Children aged 0–17 comprise 23.4% of patients (11,319), above Bury (LAD) (21.1%), the ICB (21.8%) and England (19.6%). Conversely, 14.5% are aged 65+ (7,018 patients), below Bury (LAD) (17.6%), the ICB (14.9%) and England (17.9%). Census usual residents show 13.8% Asian or Asian British ethnicity, above Bury (LAD) (10.6%), the ICB (13.6%) and England (9.6%), alongside a 19.8% non-White population. Ethnicity reflects area residents rather than registered patients, while projected list growth of 0.8% to 2030 rests on unverified methodology.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bury (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bury LA) | 2,139 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bury LA) | 1,051 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bury LA) | 21.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 prevalence reaches 46.2% PCN-wide but spans 78.5 percentage points between member practices
Core20 registered prevalence is 46.2% (average IMD decile 3.8), exceeding Bury (LAD) at 27.9%, the ICB at 40.7%, and England at 21.0%. Denominators require reconciliation before targeting: practice estimates sum to 23,388 patients, while resident deciles 1 and 2 total 17,800. Practice concentration spans 78.5 pp, led by Huntley Mount Medical Centre (78.51%) and Walmersley Road Medical Practice (72.79%), whereas volume concentrates at Rock Healthcare Limited (6,073 patients) and Radcliffe Medical Practice (5,364 patients). Reconciling these bases is needed to balance neighbourhood outreach with routine recall across member practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
579
SMI register
1.17% recorded prevalence
296
Learning disability register
0.60% recorded prevalence
27
Care homes, 761 beds
In the PCN catchment
9.4%
Provide unpaid care
Bury (LAD), Census 2021
The PCN records 579 patients on the severe mental illness register (1.2%) and 296 on the learning disability register (0.6%), with 27 catchment care homes holding 761 beds. Borough estimates show 5 rough sleepers and an unpaid carer ceiling of about 4,500.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.2% (England 1.0%). Annual physical checks trail comparators: blood pressure recording is 76.2% (England 83.4%, ICB 83.4%) and BMI recording is 75.3% (England 82.1%), which could reflect uneven recall; practice audit could test this.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,910
Hypertension register
+8.04%
Register growth, 3 yrs
Bury (LAD) +6.10% · England +5.60%
+10.49pp
BP control, under 80
≤140/90 · +6.97pp aged 80+
+1,252
More patients by 2030
Forecast 8,162 (16.23%)
Hypertension case-finding and control
Hypertension recorded prevalence is 13.9% (6,910 patients), below England (15.2%), Bury (LAD) (15.2%) and NHS Greater Manchester ICB (14.4%). Over 2023 to 2025, prevalence rose +8.0% (+1.0 pp), outpacing England (+5.6%, +0.8 pp). Blood pressure control reached 70.3% treated to target, matching England (70.3%), alongside a 3-year gain of +9.5 pp (+15.7%). Across practices, prevalence spans from 7.3% at Walmersley Road Medical Practice and 7.8% at Rock Healthcare Limited to 23.5% at Townside Surgery. Observation periods are unstated, and crude rates do not establish unmet need. Lower recorded prevalence than comparators is consistent with variation in case finding, which clinical audit could test across practices reporting the lowest rates.
Lipids and statins
Lipid-lowering therapy exceeds benchmarks, with 71.1% of QRISK ≥ 20% patients treated (England 63.6%) and 80.4% in diabetes aged 40+ without CVD (England 73.2%). CKD coverage is 78.5% (England 70.3%). Higher coverage than England indicates strong preventive management, providing an opportunity to sustain proactive prescribing across all practices.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 90,768 | £2.10 | £1.94 | £1.86 | £190,613 |
| Cardiovascular (all), 2025 | 109,109 | £3.80 | £3.15 | £3.33 | £414,614 |
In 2026, the PCN prescribed 90,768 lipid-modifying items at £2.10 per item (England £1.86, Bury (LAD) £1.91, NHS Greater Manchester ICB £1.94), spending £21,784 more than at England's unit cost, which may reflect formulary mix rather than inefficiency; prescribing audit could test this. Higher unit cost than England highlights an opportunity to review lipid-modifying choices against ICB formularies.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−1.76%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.02%
Asthma prevalence, PCN 3-yr % change
COPD review coverage reached 83.5% (England 76.4%, Bury (LAD) 77.8%), with three-year growth of +14.4% (England +2.8%). Conversely, asthma review coverage is 62.5% (England 65.7%, Bury (LAD) 64.2%), with a three-year change of -1.8% (England +4.4%, Bury (LAD) +17.6%), leaving an estimated 1,190 of 3,171 registered patients unreviewed. Paediatric asthma prescribing reached 1,907 items per 1,000 aged 5-19 (England 1,488), while second-hand smoking status recording is 82.6% (England 78.8%). Lower asthma reviews despite high prescribing may indicate uneven recall, which practice audit could test.
Cancer register and children's immunisation
Cancer register prevalence is 2.8% (1,401 patients), below England (3.8%) and Bury (LAD) (4.0%). In Q1 2025/26, MMR1 coverage at age 5 reached 92.5% (England 91.7%), but MMR2 was 80.6% (England 82.8%), an 11.9 pp dose difference reaching 23.2 pp at Rock Healthcare Limited. Pre-school 4-in-1 booster coverage is 71.9% (England 80.9%), which record audit could examine.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage were diagnosed at stage 1 or 2 (6,491 of 11,679), above England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staging was known for 70.8% of registered cancers (England 67.0%). In 2022, an estimated 2,268.2 extra early-stage cases would be required across the ICB to reach 75%. PCN recorded cancer prevalence is 2.8% (1,401 patients). Cervical screening coverage at ages 25-49 is 61.4% (Bury (LAD) 67.4%) and breast screening coverage at ages 53-70 is 68.7% (Bury (LAD) 73.8%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For the 62-day cancer referral to treatment standard, Bolton NHS Foundation Trust was 15.3 pp below the 85.0% standard, while NHS Greater Manchester Integrated Care Board was 9.3 pp below standard. On the 28-day faster diagnosis standard, Bolton NHS Foundation Trust exceeded the 75.0% standard by 5.5 pp, and NHS Greater Manchester Integrated Care Board exceeded it by 4.5 pp. On the 31-day combined treatment standard, Bolton NHS Foundation Trust exceeded the 96.0% standard by 0.5 pp, and NHS Greater Manchester Integrated Care Board exceeded it by 0.5 pp. These wider-system figures describe provider performance rather than PCN referrals.
| Pathways within standard (%) | Bolton | Northern Care Alliance | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | Manchester | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 11.68 | 21.40 |
| CT | 19.40 | 4.10 | 14.66 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 4.91 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 4.51 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 8.98 | 23.14 |
| Community services activity | Bury residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 58,875 | 573,310 |
| Referrals | 7,435 | 94,470 |
| Patients with a contact | 16,745 | 183,535 |
Community services (residents of Bury), Jun 2026 (provisional). In provisional data for June 2026, adults aged 65 and over accounted for 43.7% of community service contacts among Bury borough residents (25,735 of 58,875 contacts). These community-level figures describe resident activity across the local authority rather than PCN-specific activity.
Practice variation and patient experience
Practice vaccination achievement spans 64.9 pp across member practices in 2025/26
In 2025/26, QOF clinical-domain achievement was 100.0% at Walmersley Road Medical Practice. Vaccination and immunisation achievement spanned 64.9 pp, from 15.6% at Knowsley Medical Centre, Rock Healthcare Limited, and Walmersley Road Medical Practice to 80.5% at Ramsbottom Medical Practice (England 55.2%). Rock Healthcare Limited reported a 19.6% personalised care adjustment rate across all domains.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Radcliffe Medical | 113 | 46.9 | 68.5% | 80.3% | 87.5% |
| Knowsley | 101 | 68.5 | 59.3% | 83.2% | 78.7% |
| Walmersley Road | 108 | 72.8 | 57.1% | 77.2% | 76.3% |
| Huntley Mount | 105 | 78.5 | 78.6% | 60.9% | 76.0% |
| Townside Surgery | 95 | 49.9 | 69.9% | 71.1% | 71.7% |
| Ramsbottom | 105 | 0.0 | 46.2% | 58.7% | 65.3% |
| Monarch | 97 | 34.9 | 54.2% | 77.3% | 63.9% |
| Rock Healthcare | 91 | 65.5 | 38.4% | 75.7% | 55.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia prevalence fell 5.4% over three years while England rose +6.0%
Over 2023 to 2025, heart failure reviews fell 3.1% (England +8.7%) and dementia prevalence fell 5.4% (England +6.0%, Bury (LAD) +1.2%), while asthma reviews fell 1.8% (England +4.4%). In contrast, hypertension treated to target rose +15.7% (England +3.6%), BP control under 80 rose +18.3% (England +3.2%), and COPD reviews rose +14.4% (England +2.8%). Current heart failure reviews span from 37.3% at Knowsley Medical Centre to 93.8% at Walmersley Road Medical Practice. This variation could reflect differing practice recall protocols, which local clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
Asthma reviews
COPD register
Alcohol record (psychosis)
BP control, under 80
Hypertension treated to target
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bury (LAD) | Asset | PCN | Bury (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (761 beds) | n/a | Schools (catchment) | 85 | n/a |
| Children's centres | 4 | 8 | Places of worship | 46 | 107 |
| Libraries | 5 | 12 | Primary schools (LA maintained) | 11 | 25 |
| Primary academies | 15 | 33 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured annual asthma review recall
Asthma review coverage is 62.5% (England 65.7%, Bury (LAD) 64.2%, ICB 66.2%) after falling 1.8% (1.1 pp) over 2023 to 2025, leaving a scale estimate of 1,190 of 3,171 patients unreviewed. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Dementia register coding and care-home audit
Recorded dementia prevalence is 0.6% (287 patients) against 0.8% in England and 0.9% in Bury (LAD), giving an unadjusted benchmark gap range of +91 to +143 patients across the 48,358 list. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Option 3
Combined SMI annual physical health checks
Across the 579 patients on the SMI register (1.2% prevalence), 12-month blood pressure recording is 76.2% (England 83.4%, Bury (LAD) 77.9%, ICB 83.4%) and BMI recording is 75.3% (England 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally adapted primary care outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school second dose MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Dementia register coding and care-home audit (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Option 3 · Combined SMI annual physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
